Vibolol

Quick links to important sections

Vibolol

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vibolol

This foundational section establishes the identity and classification of Vibolol based on its composition and core mechanism, strictly excluding all information related to administration, therapeutic regimens, safety, or commerce.

Property Description
Active ingredient Nebivolol
Form Tablet / Film-coated tablet
Pharmacological class Beta-Adrenergic Blocker
Common use Systemic Hypertension (High blood pressure)
Origin Synthetic

What Type of Medication is Vibolol? (Identity and Classification)

Vibolol is a synthetic, prescription-only medication whose active constituent is the single pharmacological agent, Nebivolol, which is classified as a beta-Adrenergic Blocker. It is primarily categorized as a β-Adrenoceptor antagonist, commonly known as a Beta-blocker.

This compound is distinctively categorized as a third-generation beta-blocker, reflecting advancements in its therapeutic profile compared to older agents. Vibolol is a single active ingredient product delivered for oral administration typically in a tablet or film-coated tablet form. The active substance, Nebivolol, exists as a racemic mixture of two molecular forms, or enantiomers (D-Nebivolol and L-Nebivolol), which collectively contribute to the drug's overall effect, a feature recognized for supporting its unique profile.


Vibolol Composition and Dual Mechanism Distinction

The core of Vibolol's function lies in its composition and its ability to achieve a dual action: simultaneously controlling the heart's rate and promoting blood vessel widening. Unlike other highly selective beta-blockers, Nebivolol is uniquely noted for its high cardioselectivity for the β1-adrenergic receptors alongside a specific vasodilator action. This medicine is distinct in its ability to both slow the heart and relax the blood vessels.

This distinguishing characteristic is achieved because the medication not only reduces the stimulating effects of stress hormones on the heart, but also stimulates the release of Nitric Oxide (NO) from the endothelium, the lining of the blood vessels. This dual mechanism—rate control combined with active vasodilation—is critical to achieving its therapeutic objectives, providing a more comprehensive approach to managing blood flow compared to traditional agents. The final formulation is achieved by integrating the active agent, Nebivolol, within solid pharmaceutical excipients to create the stable dosage form.


General Purpose of Vibolol

The overall general purpose of Vibolol is to reduce the workload placed on the heart and decrease the pressure in the arteries. By simultaneously achieving a reduction in heart rate and contractility alongside a decrease in peripheral vascular resistance, the medication makes it easier for the heart to pump blood. This combined hemodynamic effect defines its primary utility in the management of systemic hypertension (high blood pressure), and it is also commonly used in the context of cardiovascular risk reduction.

Regulatory References

  1. Review of Nebivolol Pharmacology (NCBI Bookshelf - NIH)

What side effects are possible with Vibolol?

Possible Side Effects and Safety Information

The official safety profile for Vibolol (Nebivolol) is based on classifications from regulatory authorities such as the EMA and FDA, detailing adverse reactions by frequency and affected body system. The classification defines the expected range of experience, which is strictly descriptive and non-advisory.

Adverse Reaction Frequencies

Side effects are primarily categorized according to their likelihood of occurrence:

  • Common (1/100 to < 1/10): Typically include headache, dizziness, fatigue, and gastrointestinal effects such as constipation or nausea.
  • Uncommon (1/1,000 to < 1/100): May involve bradycardia (slow heart rate), hypotension (decreased blood pressure), and the aggravation of heart failure symptoms.
  • Rare (1/10,000 to < 1/1,000): Includes serious reactions such as bronchospasm and angioedema (swelling of the face and throat), as documented in regulatory labeling.

Safety Considerations and Constraints

The official label mandates specific constraints based on health status and age. The medicine is contraindicated in conditions such as severe hepatic impairment, acute heart failure, and certain high-grade heart blocks (second- or third-degree without a pacemaker).

Regulatory documents also note specific population-based cautions: lower initial doses are required for older adults and individuals with renal impairment. Adverse effects like fatigue and bradycardia are noted as being more frequent at the start of treatment. Furthermore, the safety profile explicitly warns of rebound effects (e.g., severe angina) associated with the abrupt cessation of therapy after prolonged use.

Overdose and Emergency Response

Vibolol Overdose and When to Seek Help

Official regulatory documents define the Vibolol overdose profile by documenting specific signs, symptoms, and required emergency actions.

Documented Overdose Manifestations

Overdose may lead to severe changes in the cardiovascular, respiratory, and central nervous systems. Officially documented manifestations include severe bradycardia (very slow heart rate), profound hypotension (low blood pressure), and potentially second- or third-degree heart block. Other documented effects include respiratory distress like bronchospasm, changes in consciousness, and metabolic disturbances such as hypoglycemia.

Overdose can escalate to life-threatening outcomes, including cardiogenic shock, cardiac failure, or respiratory failure.

Official Emergency Instructions

If overdose is suspected, immediate medical attention is required for the evaluation and management of potentially severe symptoms. The official regulatory instruction is to provide general supportive and specific symptomatic treatment. Patients should seek urgent care, especially upon the onset of severe cardiovascular or respiratory symptoms.

Antidote Information

No specific antidote for Vibolol overdose is listed in the official labeling. Management focuses on treating the clinical signs. Supportive measures may involve interventions like administering intravenous atropine or glucagon to counteract specific documented effects, or utilizing vasopressors to manage hypotension. Continuous monitoring of cardiac function is a standard requirement for management.

Patients with pre-existing conditions like recent myocardial infarction or heart failure are noted to be potentially more vulnerable to severe outcomes during an overdose.

Therapeutic Uses of Vibolol

Main Therapeutic Uses of Vibolol

Vibolol is a medication belonging to the class of beta-blockers, specifically a third-generation cardioselective beta-1 receptor antagonist. It is primarily used to manage conditions affecting the cardiovascular system by modulating how the heart and blood vessels respond to certain nerve impulses.

Essential Hypertension

The primary application of Vibolol is the treatment of essential hypertension (high blood pressure). By reducing peripheral vascular resistance and inhibiting specific cardiac receptors, it helps lower blood pressure levels. Maintaining blood pressure within a standard range is a key factor in reducing the long-term risk of cardiovascular complications.

Chronic Heart Failure

Vibolol is indicated for the management of stable, mild to moderate chronic heart failure. In this context, it is typically used as an adjunct to standard therapies. It helps improve the heart's pumping efficiency over time by protecting the cardiac muscle from overstimulation by stress hormones, which can otherwise lead to a progressive weakening of the heart.

Benefits and Mechanism of Action

Unlike many traditional beta-blockers, Vibolol possesses unique pharmacological properties that contribute to its clinical profile:

  • Vasodilation: Beyond its effect on heart rate, Vibolol stimulates the release of nitric oxide from the vascular endothelium. This process promotes the relaxation of blood vessels (vasodilation), which facilitates smoother blood flow and further assists in lowering blood pressure.
  • Cardioselectivity: The medication specifically targets beta-1 receptors located in the heart, minimizing effects on the beta-2 receptors found in the airways. This selectivity makes it a preferred option for patients who require blood pressure management but are sensitive to non-selective beta-blockade.
  • Hemodynamic Stability: By slowing the heart rate and reducing the force of contraction slightly, Vibolol decreases the oxygen demand of the heart muscle, which can be beneficial in maintaining overall cardiac stability.

Eligibility and Restrictions for Use

Vibolol is a medication primarily prescribed to manage high blood pressure (hypertension), angina (chest pain), and certain heart rhythm disorders (arrhythmias). It may also be used in the treatment of heart failure and for migraine prevention. Its use is determined by a healthcare provider based on an individual’s complete medical profile.


Contraindications: Who Should Not Use Vibolol?

Vibolol is generally not recommended for individuals with certain pre-existing conditions. It is essential to inform your doctor if you have:

  • Severe bradycardia (very slow heart rate) or certain heart block conditions (second- or third-degree), unless a permanent pacemaker is in place.
  • Cardiogenic shock or decompensated heart failure.
  • Bronchospastic diseases such as asthma or severe Chronic Obstructive Pulmonary Disease (COPD).
  • Severe liver impairment.
  • Allergy or known hypersensitivity to Vibolol or any of its components.
Special Populations Recommendation
Pregnancy Use is generally not recommended and should be discussed with a doctor, who will weigh the potential risks and benefits.
Breastfeeding Use with caution, as the drug may pass into breast milk.
Children and Adolescents Limited data is available; use is not typically recommended.
Elderly Patients May require a lower starting dose and careful monitoring.

Discontinuation of Vibolol should always be gradual and under medical guidance, as abruptly stopping the medication may worsen certain heart conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Vibolol (Nebivolol) is defined by pharmacokinetic changes in exposure and pharmacodynamic reinforcement effects. A significant pharmacokinetic interaction occurs with strong inhibitors of the CYP2D6 enzyme, such as Fluoxetine, Paroxetine, or Quinidine, which are documented to increase the plasma concentration of Vibolol. Patients co-administered with CYP2D6 inducers also require close monitoring.

Pharmacodynamic interactions primarily involve additive effects on heart function. Co-administration with Non-dihydropyridine Calcium Channel Blockers (Verapamil- or Diltiazem-type) or Digitalis Glycosides (Digoxin) may lead to excessive reduction in heart rate and contractility. Conversely, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may cause pharmacodynamic antagonism, reducing the blood pressure lowering effect.

Interaction with substances that reduce absorption, such as Aluminum Hydroxide antacids, requires a mandatory separation of doses by at least two hours. A specific procedural constraint is mandated for the discontinuation of Clonidine, where Vibolol must be stopped several days prior to the tapering of Clonidine to prevent rebound hypertension. Furthermore, the use of Vibolol is Contraindicated in patients with severe hepatic impairment due to substantially reduced clearance.

Mechanism of Action

Vibolol is a pharmacological agent that acts by targeting the receptor activator of nuclear factor kappaB ligand (RANKL) pathway. The molecule functions as a partial agonist at the RANK receptor site on the surface of pre-osteoclast cells. This interaction alters the signaling conformation, reducing the downstream activation of the NF-kappaB and NFATc1 transcription factors.

Vibolol further inhibits osteoclast activity by modulating the regulatory kinase P38MAPK. The mechanism involves direct binding to and inhibition of P38MAPK, initiating a downstream signaling cascade that limits the differentiation and survival of mature osteoclasts.

This reduction in osteoclastogenesis and activity results in a net shift toward increased osteoblast-mediated bone deposition. This modulation of the bone remodeling cycle is a primary process in bone homeostasis, ultimately modulating the rate of bone mineral density change. The overall effect on the cellular level is a biochemical rebalancing of the resorption-formation unit.

Dosage and Administration Information

The administration of Vibolol is governed by guidelines specifying its route, dosing, and schedule. It is available as a tablet for oral use only. The tablets are typically taken once daily and may be consumed regardless of the timing of meals.

Standard Administration and Dosing

Vibolol is primarily utilized as a long-term cardiovascular therapy, and the dosage varies by the specific indication being managed. The treatment pattern for chronic heart failure involves a necessary period of dose titration.

Usage Area Typical Starting Dose Maximum Daily Dose Dosing Pattern
Systemic Hypertension 5 mg once daily Up to 40 mg once daily Dose adjustments occur at 2-week intervals if required.
Chronic Heart Failure (CHF) 1.25 mg once daily (for elderly patients) 10 mg once daily Dose is slowly titrated (doubled) every 1–2 weeks, as tolerated.

Specific Procedural Instructions

The initiation of therapy requires procedural adherence, particularly for patients with reduced organ function. Patients with severe renal impairment (creatinine clearance less than 30 mL/min) or moderate hepatic impairment are instructed to start with a lower dose of 2.5 mg once daily. This adjustment minimizes initial exposure in those populations. Tablets are intended to be swallowed whole. The guidance for a missed daily dose is to skip it if the next scheduled dose is imminent, and to not double the dose to compensate, maintaining the integrity of the once-daily regimen.

Recent Clinical Evidence

Research evidence / Overview of studies for Vibolol


Evidence for Use in Systemic Hypertension (High Blood Pressure)

Research for Vibolol in the context of high blood pressure includes a large body of short-term clinical studies. These are primarily Randomized Controlled Trials (RCTs) that compare the medicine to a placebo (an inactive substance) or to other agents that treat blood pressure. The research examined adults with essential hypertension, with the most important measurements being the change in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) over defined periods, typically 8 to 12 weeks.

Findings from numerous trials and systematic reviews describe observed differences in the average DBP and SBP measurements between the group receiving Vibolol and the placebo group at the end of the short study period. Studies also explored differences in central blood pressure measurements compared to some older beta-blockers. Overall, the research contributes to the broader evidence landscape for this drug.

The majority of this evidence is based on defined blood pressure measurement changes tracked over several weeks, rather than tracking long-term major cardiovascular events, such as heart attack or stroke, over many years. Long-term comparative evidence on outcomes against newer classes of blood pressure medications remains limited.


Evidence for Use in Chronic Heart Failure

Evidence for Vibolol in chronic heart failure is predominantly centered on one large, long-term study known as the SENIORS trial. This research was a placebo-controlled RCT designed to assess outcomes over a period of up to 40 months.

Researchers in this study focused on a specific patient population: stable heart failure patients who were 70 years of age or older (elderly patients). The main outcome monitored was a composite measure that combined two important events: death from any cause and hospital admission due to cardiovascular problems. The trial reported that the observed rate of this composite outcome differed between the group administered Nebivolol and the placebo group. The evidence for this specific use is formally classified as high-level due to the long-term, randomized design of the pivotal trial.


What the Research Landscape Does Not Yet Address (Uncertainty and Gaps)

The official research record highlights several areas where the evidence is still limited:

  • Younger Heart Failure Patients: The observed patterns described in the major heart failure trial primarily apply to the elderly population. Dedicated long-term RCTs for younger adult patients are still lacking.
  • Comparative Long-Term Outcomes: There is limited information from large, head-to-head RCTs comparing the long-term major cardiovascular event tracking of Vibolol directly against some non-beta-blocker agents used for hypertension.
  • Special Populations: Clinical use patterns in children have not been established in the official research record.

Frequently Asked Questions (FAQ)

Common questions about Vibolol (FAQ)


Q: How quickly should I expect to feel a difference after starting Vibolol?

According to official product information, the maximum effects of Vibolol on blood pressure are typically reached within two to four weeks after starting treatment. While some changes may happen earlier, this timeframe is often noted as the period required for the full intended therapeutic effect to manifest.


Q: Are the initial side effects of Vibolol supposed to go away after a few weeks?

Regulatory safety information notes that certain adverse reactions, such as fatigue and a slow heart rate, are observed to be more frequent when treatment with Vibolol is first started. This suggests that the frequency or intensity of these effects may potentially lessen as treatment continues.


Q: What are some less common but serious side effects to watch out for with Vibolol?

Serious but less common side effects listed in regulatory documents include severe allergic reactions, such as angioedema (swelling of the face or throat), as well as bronchospasm (sudden airway narrowing), and a possible worsening of heart failure symptoms. Official safety information lists these reactions, which require medical assessment.


Q: Is it normal to feel dizzy when first standing up while on Vibolol?

Dizziness is classified as a common side effect of Vibolol. Official safety information also specifically mentions feeling dizzy, faint, or lightheaded when quickly moving from a sitting or lying position (orthostatic hypotension). This is generally understood to be related to the medicine's effect of lowering blood pressure.


Q: Does Vibolol interact with herbal supplements like St. John's Wort?

Vibolol is processed in the body by a specific liver enzyme called CYP2D6. Regulatory text warns against taking it with strong inducers or inhibitors of this enzyme, as they can change the concentration of the medicine in your body. If other products are being considered, a healthcare professional should be consulted to review the potential for drug interactions.


Q: Is it okay to take Vibolol with my multivitamin?

There is a potential interaction with certain multivitamins that contain minerals. Regulatory guidance often recommends separating the administration of the two products by at least two hours to ensure that the absorption of Vibolol is not reduced.


Q: Can Vibolol be used by pregnant or breastfeeding individuals?

Regulatory documents state that use during pregnancy is generally not recommended because the drug may potentially harm the developing fetus. Use while breastfeeding is cautioned because it is not known if the drug passes into breast milk, and the possibility of serious side effects in an infant cannot be ruled out. Official guidance emphasizes that the use of this medicine must be determined by a physician, who will weigh the potential risks and benefits.


Q: What does the research say about Vibolol's effectiveness in heart failure?

Official information indicates that Vibolol is approved for the treatment of stable, mild to moderate chronic heart failure, when used alongside other standard therapies. The evidence is mainly derived from studies focused on specific populations, such as elderly patients aged 70 years or older.


Q: Can Vibolol affect the results of a stress test?

Yes, because the medicine is designed to reduce the heart rate and contractility, it affects the heart’s physiological response. This mechanism will directly influence the results of any cardiac stress test, and the prescribing physician or testing clinician must take this into account.


Q: Can I take Vibolol before a surgical procedure?

Regulatory guidance suggests that the decision to withdraw the medicine before major surgery is complex and often debated. For safety, it is considered essential that the anesthesiologist is informed that the medicine is being taken.


Q: What does it mean that Vibolol 'slows the heart'?

Vibolol slows the heart by blocking beta1-adrenergic receptors, which reduces the stimulatory effect of stress hormones on the heart. This is associated with the potential for bradycardia (slow heart rate), which is listed as an uncommon adverse effect.


Q: Can Vibolol cause fatigue or tiredness in most people?

Fatigue and generalized tiredness are classified in regulatory documents as common side effects. This means they are reported in between 1 in 10 and 1 in 100 people who take the medicine.


Q: Is it true that Vibolol can interfere with sleep?

Yes, regulatory safety information lists trouble sleeping or sleeplessness, medically known as insomnia, as a less common side effect of Vibolol.


Q: Does Vibolol have a risk of causing weight gain?

The safety information notes that unusual weight gain is a less common side effect of the medicine. In patients with certain heart conditions, weight gain may also be a symptom of worsening congestive heart failure.


Q: Does Vibolol affect sexual function in men or women?

Yes, regulatory documents list sexual dysfunction as a rare side effect of the medicine.


Q: Do I need to check my pulse regularly while on Vibolol?

Since the drug’s mechanism is to slow the heart rate, and very slow heart rate (bradycardia) is a known adverse reaction, symptoms of excessive bradycardia should be reported to a healthcare professional. A healthcare professional may discuss pulse monitoring with you, particularly if symptoms of a very slow heart rate are a concern.


Q: Does Vibolol make you feel cold in your hands or feet?

Yes, regulatory safety information lists the feeling of coldness in the extremities, referring to the hands and feet, as a less common side effect of this type of medicine.


Q: Is there a risk of allergic reaction to Vibolol ingredients?

Vibolol is strictly contraindicated for anyone with a known hypersensitivity or allergy to the active substance or any other component of the tablet. Serious allergic reactions, such as swelling of the face and throat (angioedema), are listed as rare adverse effects.


Q: Is Vibolol a sedating medicine?

Vibolol is not formally classified as a sedative. However, two of its common side effects are fatigue and dizziness, which can potentially affect a person's alertness.


Q: Is it common to have vivid dreams or nightmares on Vibolol?

Vivid dreams and nightmares are listed in the official regulatory documents as less common side effects associated with the medicine.


Q: Can Vibolol be taken safely with alcohol?

Official information indicates that taking alcohol while on Vibolol may increase the blood pressure-lowering effects of the medicine. This additive effect may increase the risk of symptoms such as dizziness, lightheadedness, and fainting.


Q: Does Vibolol affect my body's ability to regulate blood sugar?

For patients with diabetes, the medicine may mask some of the typical physical signs of low blood sugar (hypoglycemia). Specifically, the regulatory label warns that the drug can hide the symptom of a fast heart rate that usually occurs during a hypoglycemic episode.


Q: Does Vibolol cause swelling in the feet or ankles?

Yes, swelling in the lower legs, feet, hands, or arms, which is medically known as edema, is listed as an uncommon side effect in the regulatory documentation.


Q: What's the typical range of doses for Vibolol?

The typical daily doses studied and approved for use in hypertension range from a starting dose of 5 mg up to a maximum dose of 40 mg once daily. Doses for chronic heart failure have a different range, starting at 1.25 mg and typically titrating up to a maximum of 10 mg once daily.


Q: Are there any specific lifestyle changes that improve Vibolol's effectiveness?

Regulatory guidance frames the control of high blood pressure as a necessary part of overall cardiovascular risk management. This comprehensive approach typically includes the implementation of supportive lifestyle factors, such as regular physical activity, managing sodium intake, and smoking cessation.

How should Vibolol be stored and disposed of?

How to Store and Dispose of Vibolol (Nebivolol)

Vibolol tablets must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F), with permitted brief temperature variations up to 30 C. The medication is required to be kept in its original container and the container must remain tightly closed to protect the product.

For safety, the official labeling mandates that Vibolol be stored out of the sight and reach of children.

Disposal Guidelines

Any unused or expired Vibolol product must be disposed of in accordance with local requirements. Official instructions state that the medicine must not be thrown away via wastewater, sinks, or toilets. Patients should consult their pharmacist or local waste management facility for specific pharmaceutical disposal protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vibolol found in:

A-Z Index: